Skip to main content
. 2020 May 13;15(13):1163–1174. doi: 10.1002/cmdc.202000149

Table 2.

Data for hybrid inhibitors against Class I and Class IIb HDACs.

Cmpd

pIC50 a

HDAC1b

HDAC2b

HDAC3b

HDAC6b

HDAC8b,c

HDAC10c,d

PCI‐34051 (2a)

4.33

<4.0

4.24

5.15

7.29

4.38

Tubastatin A (1c)

5.91

4.89

5.78

7.70

5.70

7.90

3a

6.58

5.65

5.26

7.74

7.17

8.59

3b

6.21

5.27

5.16

7.12

6.78

8.55

3c

6.30

5.38

4.87

7.32

6.29

7.91

3d

6.28

5.33

5.19

7.65

7.01

8.49

3e

6.09

5.15

5.18

7.35

7.18

8.52

3f

7.06

6.14

5.88

7.82

7.37

8.47

3g

6.18

5.02

5.18

7.52

7.05

8.40

[a] See Table S1 for error values associated with these calculations. [b] Enzymatic HDAC‐GloTM I/II assay. [c] Values taken from Table 1. [d] Ligand displacement FRET assay.